In addition, treatment with clinical antgonists of kinases involved in cancer such as BRAF or c-KIT induces OXPHOS-addiction that limits drug efficacy and simultaneously induces sensitivity to OXPHOS inhibition as combination therapy [29, 85]. Here, BRAF is linked to cancer.